



41

12-05-03

1641

Please type a plus sign (+) inside this box → 

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>		Application Number	09/700,643
		Filing Date	February 2, 2001
		First Named Inventor	H. Matsumoto
		Group Art Unit	1641
		Examiner Name	B. Nguyen
Total Number of Pages in This Submission	5	Attorney Docket Number	2523 US0P

RECEIVED  
DEC 10 2003  
TECH CENTER 1600/2900

<b>ENCLOSURES (check all that apply)</b>		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers <i>(for an Application)</i> <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i> <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i> Return Postcard. Election of Claims
Remarks		The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 500799.

<b>SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT</b>	
Firm or Individual name	Elaine M. Ramesh, Ph.D., JD, Reg. No. 37,293
Signature	<i>Elaine M. Ramesh</i>
Date	12/4/03

<b>CERTIFICATE OF MAILING</b>	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: <input type="text"/>	
Typed or printed name	
Signature	
Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

*Express Mail EV 310944467 US*



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/700,643  
Filed: February 2, 2001  
1<sup>st</sup> Inventor: H. Matsumoto  
For: Antibody and Use Thereof  
Atty. Dkt. No. 2523 US0P

Art Unit: 1641  
Examiner: B. Nguyen  
Allowed:  
Batch:  
Paper No.: 14

Election of Claims

RECEIVED

DEC 1 0 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TECH CENTER 1600/2900

Dear Sir:

In response to the restriction requirement in the Office Action mailed November 10, 2003 (Paper No. 13), Applicants elect to prosecute claims of Group V, species C which is P2L-1Ca in the present application, with traverse.

Applicants assert that prosecution of the claims of Group V jointly with the claims of other groups related to monoclonal antibody P2L-1Ca would not place an undue burden on the Examiner. Specifically, Applicants assert that the claims of Groups I-A, II-C and IV-C should be prosecuted along with the claims of Group V, if the species C is to be focused upon.

No amendment of inventorship is necessitated by this election.

Early allowance of the claims is requested. Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully invited to call Applicants' attorney at the number below.

Respectfully submitted,

Date: December 4, 2003

(847) 383-3391  
(847) 383-3372

*Elaine M. Ramesh*  
Elaine M. Ramesh, Ph.D., Reg. No. 43,032  
Mark Chao, Ph.D., Reg. No. 37,293  
Attorney for Applicants  
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
Suite 500, 475 Half Day Road  
Lincolnshire, IL 60069 USA

**Certificate of Mailing under 37 CFR 1.10**

The undersigned hereby certifies that this document, along with any attachments, is being deposited in an envelope addressed to The Commissioner of Patents and Trademarks, with sufficient postage with the United States Postal Service EXPRESS MAIL Post Office to Addressee Service on this date December 4, 2003.

Express Mail Label No. EV 310944467 US

Gail L. Winokur  
Printed Name: Gail L. Winokur